Fresh analysis reveals that people who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end traditional lifestyle programs.
Published data in a prominent medical journal shows that while overweight people often shed substantial amounts of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing such medications should be informed of the danger of rapid rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment mass in about 18 months.
Analyzing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of the injectable medications with older methods.
Researchers emphasize that people who lose weight through diet and exercise typically have a less rapid weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Regain
Doctors propose the mode of action of the injections is key to understanding the accelerated weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Sustained high doses of the hormone concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement results in appetite is no longer kept in check, making excessive eating far more likely."
A Chronic Issue?
Health authorities advise the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians argue that, due to the likelihood of weight regain, the therapy should be considered long-term.
This perspective is supported by pharmaceutical companies, who state that the results "underscore the long-term character of excess weight," similar to managing diseases like high blood pressure.
Patient Experiences
Individuals who have stopped the medication explain a sudden resurgence of cravings.
"It felt as if a trigger activating and you become starving," said a patient.
The struggle is compounded if users have not adopted lasting lifestyle or habit modifications during therapy.
Growing Adoption
Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is greater among women than males.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than the NHS.
In conclusion, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a standalone fix and maintained weight loss relies on ongoing behavioural management.
